Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group.
暂无分享,去创建一个
D. Cella | S. Adak | J. Schiller | D. Johnson | R. Devore | S. Adak | R. Devore | J. Schiller | David H. Johnson
[1] K. Mori,et al. A randomized phase III study of irinotecan and cisplatin (CP) versus etoposide and cisplatin (EP) in extensive-disease small-cell lung cancer (ED-SCLC): Japan Clinical Oncology Group Study (JCOG 9511) , 2000 .
[2] J. von Pawel,et al. Topotecan in the Therapy of Brain Metastases in Lung Cancer , 1998, Oncology Research and Treatment.
[3] C. Sotiriou,et al. Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. , 1998, Lung cancer.
[4] D S Tulsky,et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] W. Hong,et al. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Glick,et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] S. Sallan,et al. Phase II evaluation of topotecan for pediatric central nervous system tumors , 1996 .
[8] J. Beijnen,et al. Clinical Pharmacokinetics of Topotecan , 1996, Clinical pharmacokinetics.
[9] E. Eisenhauer,et al. Phase II study of topotecan in patients with recurrent malignant glioma , 1996 .
[10] D. Tulsky,et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. , 1995, Lung cancer.
[11] S. Steinberg,et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] G. Giaccone,et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] F. Balis,et al. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. , 1993, Cancer research.
[14] Y. Pommier,et al. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. , 1992, European journal of cancer.
[15] R. Kim,et al. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice , 1992, International journal of cancer.
[16] S. Kaufmann,et al. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. , 1991, Cancer research.
[17] D. Ettinger,et al. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Partridge,et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. , 1989, British Journal of Cancer.
[19] J. Crawford,et al. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] C. Perez,et al. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] P. O'Brien,et al. A multiple testing procedure for clinical trials. , 1979, Biometrics.
[22] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[23] F. Wilcoxon. Individual Comparisons by Ranking Methods , 1945 .
[24] J. Bonner,et al. The significance of the sequence of administration of topotecan and etoposide , 1996, Cancer Chemotherapy and Pharmacology.
[25] David R. Cox,et al. Regression models and life tables (with discussion , 1972 .